BELITE BIO, INC

Developing novel oral therapies for retinal degenerative eye diseases like GA and Stargardt disease.

BLTE | US

Overview

Corporate Details

ISIN(s):: US07782B1044
LEI:
Country:: United States of America
Address:: 12750 HIGH BLUFF DRIVE SUITE 475, 92130 SAN DIEGO
Website:: https://belitebio.com/
Sector:: Manufacturing
Industry:: Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Belite Bio, Inc. is a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics for retinal degenerative eye diseases with significant unmet medical needs. The company's primary targets include atrophic age-related macular degeneration (specifically Geographic Atrophy, or GA) and Stargardt disease (STGD1). Its therapeutic pipeline is built on a proprietary portfolio targeting Retinol Binding Protein 4 (RBP4). The lead candidate, Tinlarebant (LBS-008), is a novel oral therapy designed to reduce the accumulation of ocular toxins that contribute to disease progression. Tinlarebant is in late-stage development with multiple Phase 3 trials and has received numerous regulatory designations, including Orphan Drug, Fast Track, Breakthrough Therapy, and Rare Pediatric Disease designations in the U.S. and other key markets.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Bulk Actions:

	Date	Filing	Language	Size	Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all BELITE BIO, INC filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for BELITE BIO, INC

This data is available as part of our premium data solutions. Contact our team for access.

Request This Data

Need More History? Access decades of standardized financials for BELITE BIO, INC via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

Company	Country	Ticker
StemRIM Inc. Developing regenerative medicines that use the body's own stem cells to treat intractable diseases.	Japan	4599
STENOCARE A/S Develops and distributes prescription medical cannabis oils in Northern Europe and Australia.	Denmark	STENO
Stoke Therapeutics, Inc. Developing RNA-based medicines for genetic diseases by increasing protein from the healthy gene.	United States of America	STOK
ST PHARM CO., LTD. A global CDMO specializing in APIs and RNA therapeutics for the gene therapy market.	South Korea	237690
Structure Therapeutics Inc. Develops oral small molecule drugs for chronic conditions like metabolic diseases and obesity.	United States of America	GPCR
Sugentech, Inc. Develops advanced in-vitro diagnostic systems for hospitals, clinics, and at-home use.	South Korea	253840
SUHEUNG CO.,LTD. Global manufacturer of capsules and contract manufacturing for pharma/nutraceutical industries.	South Korea	008490
Sumitomo Pharma Co., Ltd. R&D pharma creating medicines for oncology, psychiatry & neurology, focusing on Japan & the US.	Japan	4506
Summit Therapeutics Inc. Advancing a Phase 3 bispecific antibody for lung cancer and other solid tumors.	United States of America	SMMT
SunBio, Inc. Develops biopharmaceuticals and devices like artificial blood using proprietary PEGylation technology.	South Korea	067370